Literature DB >> 12725542

Treatment of urinary tract infection with gentamicin once or three times daily.

C Y Chong1, A S L Tan, W Ng, A Tan-Kendrick, A Balakrishnan, S M Chao.   

Abstract

AIM: To examine the safety and efficacy of once-daily (OD) gentamicin treatment compared with conventional 8-hourly dosing (TDS) for urinary tract infection (UTI).
METHODS: This was a prospective, randomized, controlled trial of children 1 mo to 13 y of age with presumed UTI. Children were randomly assigned to OD gentamicin 5 mg kg(-1) d(-1) or TDS gentamicin 6 mg kg(-1) d(-1) divided 8 hourly. Microbiological efficacy, nephrotoxicity, ototoxicity and renal scarring were assessed at the end of treatment.
RESULTS: 210 patients with presumed UTI were recruited, of whom 172 were analysable (OD 84, TDS 88). The median age was 7 mo, 50% were male and 74% (n = 127) of patients had pyelonephritis. The majority of infections were due to Escherichia coli (n = 153, 89%), of which 9 (5.2%) were bacteraemic. Comparing the two groups, there was no significant difference in age, gender, duration of fever before admission, pyuria, nitrite positivity or initial total white blood cell count. All patients had negative urine cultures after 2-3 d of treatment, demonstrating 100% microbiological efficacy. There was no difference between the two groups in terms of ototoxicity, nephrotoxicity, duration of gentamicin treatment or time to fever defervescence.
CONCLUSION: OD gentamicin is as efficacious as TDS gentamicin in the treatment of UTI in children, with no difference in ototoxicity and nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12725542

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

1.  Treatment of acute pyelonephritis in children.

Authors:  Jonathan C Craig; Elisabeth M Hodson
Journal:  BMJ       Date:  2004-01-24

2.  Antimicrobial susceptibility of pediatric uropathogens in Thrace, Greece.

Authors:  Elpis Mantadakis; Aggelos Tsalkidis; Maria Panopoulou; Spyridon Pagkalis; Gregory Tripsianis; Mathew E Falagas; Mathew Falagas; Sophia Kartali-Ktenidou; Athanassios Chatzimichael
Journal:  Int Urol Nephrol       Date:  2010-06-04       Impact factor: 2.370

3.  Antibiotics and Cure Rates in Childhood Febrile Urinary Tract Infections in Clinical Trials: A Systematic Review and Meta-analysis.

Authors:  Konstantinos Vazouras; Romain Basmaci; Julia Bielicki; Laura Folgori; Theoklis Zaoutis; Mike Sharland; Yingfen Hsia
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

4.  Development of kidney scars after acute uncomplicated pyelonephritis: relationship with clinical, laboratory and imaging data at diagnosis.

Authors:  G B Piccoli; L Colla; M Burdese; C Marcuccio; E Mezza; J Maass; G Picciotto; A Sargiotto; L Besso; A Magnano; V Veglio; G Piccoli
Journal:  World J Urol       Date:  2006-01-21       Impact factor: 4.226

Review 5.  Is a once daily dose of gentamicin safe and effective in the treatment of uti in infants and children?

Authors:  M Shahid; R Cooke
Journal:  Arch Dis Child       Date:  2007-09       Impact factor: 3.791

6.  High-Dose, Extended-Interval Gentamicin and Tobramycin for Pediatric Inpatients: A Survey of Canadian Hospital Pharmacists.

Authors:  Caitlin Roy; Carolyn Gray; Lisa Ruda; Ali Bell; Jennifer Bolt
Journal:  Can J Hosp Pharm       Date:  2016-10-31

7.  Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis.

Authors:  Paola Pansa; Yingfen Hsia; Julia Bielicki; Irja Lutsar; A Sarah Walker; Mike Sharland; Laura Folgori
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

8.  Interaction between gentamicin and mycophenolate mofetil in experimentally induced pyelonephritis.

Authors:  H Malekinejad; A Nikibakhsh; S Gholizadeh-Soltani; A Farshid
Journal:  Indian J Nephrol       Date:  2012-01

Review 9.  Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.

Authors:  F A Diepstraten; A E Hoetink; M van Grotel; A D R Huitema; R J Stokroos; M M van den Heuvel-Eibrink; A J M Meijer
Journal:  JAC Antimicrob Resist       Date:  2021-12-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.